Pay in 4 interest-free payments of $7.12 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
The TRIUMPH-1 Phase 3 clinical trial results, announced in May 2026, showcased participants losing up to 28.3% of their body weight over 80 weeks, indicating significant promise compared to other options like tirzepatide (Zepbound) and semaglutide (Wegovy)
A sensitivity analysis excluding the ITCA trial yielded consistent results (HR (95%CI): 0.83 (0.750.93)
Is ESG better than taking weight loss medication
M.BeltermanC
Underlying Health Conditions or Medications Certain conditions, like type 2 diabetes, hormonal imbalances, thyroid issues, or sleep apnea, can blunt weight-loss response
Injectable GLP-1s are generally more effective because they bypass the digestive system, leading to better absorption in the bloodstream
US$ 24.72
US$ 27.53
US$ 21.42
US$ 24.01
US$ 27.66
US$ 29.62
US$ 27.69
